Qiagen (QGEN) Panoramica del titolo
Qiagen N.V. fornisce soluzioni sample to insight che trasformano i campioni biologici in approfondimenti molecolari in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 3/6 |
QGEN Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Qiagen N.V.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$42.50 |
| Massimo di 52 settimane | US$57.82 |
| Minimo di 52 settimane | US$32.53 |
| Beta | 0.63 |
| Variazione di 1 mese | -3.08% |
| Variazione a 3 mesi | 13.58% |
| Variazione di 1 anno | -12.25% |
| Variazione a 3 anni | -8.93% |
| Variazione a 5 anni | -28.82% |
| Variazione dall'IPO | 1,839.34% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento narrativa • Aug 22
QGEN: Pipeline Progress And Takeover Interest Will Shape Medium Term Outlook
Qiagen's analyst fair value estimate has shifted from $36.00 to about $40.11. This change reflects updated assumptions around modestly higher revenue growth, profitability and future P/E multiples that broadly align with recent Street price target moves into the low to mid $40s.
Aggiornamento narrativa • Aug 07
QGEN: Post Pandemic Testing And Takeover Interest Will Shape Oncology And Diagnostics Outlook
Qiagen's analyst price target has been revised higher to $45.28 from $43.96 as analysts factor in updated Q2 commentary, mixed but generally higher Street targets in the $36 to $48 range, and modest adjustments to growth and profitability assumptions. Analyst Commentary Recent Street research on Qiagen points to a mix of optimism and caution.
Aggiornamento narrativa • Jul 23
QGEN: Takeover Interest Will Drive Reassessment Of Core Life Science Franchise
Qiagen's updated analyst price target has moved lower from about $55.91 to $49.47, reflecting mixed Street research. Several firms trimmed targets on QuantiFERON uncertainty, while others maintained Hold or moved to more positive stances, citing a solid life science franchise and potential growth inflection.Seeking Alpha • Jul 12
Qiagen: New Launches Signal A Turnaround
Summary Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation. QGEN trades at a discount to peers on P/S multiples, yet demonstrates higher forward growth potential, reinforcing bullish upside momentum. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 09
QGEN: Reset Expectations And Product Pipeline Will Shape Medium Term Outlook
Analysts now place Qiagen's fair value at $36, down from $38. This reflects a reset in expectations around QuantiFERON growth and recent price target reductions, which offset more constructive views on the stock's longer term positioning and valuation.Aggiornamento narrativa • Jun 25
QGEN: Expect Post Pandemic Testing Demand To Support Oncology And Diagnostics Expansion
Analysts have adjusted the fair value estimate for Qiagen slightly higher to $43.96 from $43.82, reflecting a modestly higher discount rate, alongside mixed recent price target moves that highlight both concerns over growth in areas like QuantiFERON and renewed interest in the stock as a potential structural beneficiary of post pandemic demand trends. Analyst Commentary Recent Street research on Qiagen reflects a split view, with some bullish analysts pointing to potential growth opportunities and valuation support, while more cautious analysts focus on execution risks and reduced expectations in key product areas.Articolo di analisi • Jun 21
Qiagen (QGEN) Stock Could Be 15.7% Undervalued After QIAcuity Expansion
Qiagen (NYSE:QGEN) is in focus after announcing new additions to its QIAcuity digital PCR ecosystem, including expanded gene expression tools, higher multiplexing and upgraded software and automation for high throughput labs. See our latest analysis for Qiagen. The QIAcuity update comes as Qiagen’s share price has shown mixed momentum, with a 1-month share price return of 5.06%, a year-to-date share price return that is down 22.32%, and a 5-year total shareholder return that is down 23.67%...Aggiornamento narrativa • Jun 06
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostics Expansion Beyond Current Headwinds
Qiagen's updated analyst price target has been reduced by about $9.70. This reflects analysts' lower growth and profitability assumptions after recent cuts across the Street tied to softer QuantiFERON trends and a rebased full year outlook.Nuova narrativa • May 15
Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?Nuova narrativa • Apr 30
Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Apr 29
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion
Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.Aggiornamento narrativa • Apr 10
QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns
Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.Aggiornamento narrativa • Mar 27
QGEN: Possible Sale Prospects Are Expected To Drive Future Returns
The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.Aggiornamento narrativa • Mar 12
QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns
The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.Aggiornamento narrativa • Feb 25
QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside
Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.Aggiornamento narrativa • Feb 11
QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks
Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.Aggiornamento narrativa • Jan 28
QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition
Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.Aggiornamento narrativa • Jan 08
QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions
Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).Articolo di analisi • Jan 07
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued
Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...Aggiornamento narrativa • Dec 14
QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead
Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.Aggiornamento narrativa • Nov 29
QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms
Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.Aggiornamento narrativa • Nov 15
QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside
Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.Articolo di analisi • Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...Aggiornamento narrativa • Oct 31
QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.Aggiornamento narrativa • Oct 17
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.Aggiornamento narrativa • Oct 03
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.Aggiornamento narrativa • Sep 04
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.Rendimenti per gli azionisti
| QGEN | US Life Sciences | US Mercato | |
|---|---|---|---|
| 7D | -3.8% | -1.9% | -0.2% |
| 1Y | -12.2% | 25.5% | 14.8% |
Ritorno vs Industria: QGEN ha avuto una performance inferiore rispetto al US Life Sciences che ha registrato un rendimento 25.5 % nell'ultimo anno.
Rendimento vs Mercato: QGEN ha avuto una performance inferiore al mercato US che ha registrato un rendimento 14.8 % nell'ultimo anno.
Volatilità dei prezzi
| QGEN volatility | |
|---|---|
| QGEN Average Weekly Movement | 5.0% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: QGEN non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di QGEN è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1984 | 5,500 | Jon Pratt | www.qiagen.com |
Qiagen N.V. fornisce soluzioni sample to insight che trasformano i campioni biologici in approfondimenti molecolari in tutto il mondo. L'azienda offre materiali di consumo per la tecnologia dei campioni, come i kit di stabilizzazione e purificazione degli acidi nucleici per i materiali dei campioni, l'elaborazione manuale e automatizzata per la genotipizzazione, l'espressione genica e l'analisi virale e batterica, nonché le tecnologie delle membrane di silice e delle microsfere magnetiche; materiali di consumo per la tecnologia dei campioni secondari, compresi i kit e i componenti per la purificazione degli acidi nucleici; e strumenti per la purificazione degli acidi nucleici, il controllo di qualità e gli accessori. L'azienda fornisce anche materiali di consumo per la risposta immunitaria, come il test di rilascio dell'interferone-gamma per il test della tubercolosi e i test per il controllo post-trapianto e il monitoraggio della carica virale; materiali di consumo per l'oncologia e per la salute sessuale e riproduttiva, tra cui i test per il test prenatale e il rilevamento delle malattie sessualmente trasmissibili e dell'HPV, i test per l'analisi delle varianti genomiche e gli strumenti per l'analisi del campione, tra cui l'analisi molecolare in un'unica fase di sindromi difficili da diagnosticare e i test PCR integrati.
Qiagen N.V. Riepilogo dei fondamenti
| QGEN statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$8.76b |
| Utili (TTM) | US$409.32m |
| Ricavi(TTM) | US$2.10b |
21.5x
Rapporto P/E4.2x
Rapporto P/SQGEN è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| QGEN Conto economico (TTM) | |
|---|---|
| Ricavi | US$2.10b |
| Costo del fatturato | US$706.05m |
| Profitto lordo | US$1.39b |
| Altre spese | US$985.00m |
| Utili | US$409.32m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 1.98 |
| Margine lordo | 66.38% |
| Margine di profitto netto | 19.49% |
| Rapporto debito/patrimonio netto | 49.3% |
Come si è comportato QGEN nel lungo periodo?
Vedi performance storica e confrontoDividendi
6.5%
Rendimento attuale del dividendo18%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/09 07:19 |
| Prezzo dell'azione a fine giornata | 2026/09/09 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Qiagen N.V. è coperta da 43 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Charles Butler | Barclays |